Skip to content

CAPRICOR THERAPEUTICS, INC.: 10-Q filed 2020-11-13

What CAPRICOR THERAPEUTICS, INC. reported in its quarterly report filed 2020-11-13 (fiscal Q3 2020): 35 published measures, 98 facts as tagged in accession 0001104659-20-125153.

This filing

Form
10-Q (quarterly report)
Filed
2020-11-13
Fiscal period
fiscal Q3 2020
Accession
0001104659-20-125153 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CAPRICOR THERAPEUTICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2020-09-3036,187,057USD
At 2019-12-3111,113,637USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2020-09-305,779,138USD
At 2019-12-314,274,251USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2020-09-3030,407,919USD
At 2020-06-3031,653,954USD
At 2020-03-319,592,634USD
At 2019-12-316,839,386USD
At 2019-09-303,570,434USD
At 2019-06-302,363,783USD
At 2019-03-313,740,302USD
At 2018-12-314,615,587USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2020-09-3035,300,340USD
At 2019-12-313,899,328USD
At 2019-09-306,827,570USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-3,910,124USD92
2020-01-01 to 2020-09-30-9,479,096USD274
2020-04-01 to 2020-06-30-3,484,154USD91
2020-01-01 to 2020-03-31-2,084,818USD91
2019-07-01 to 2019-09-30-1,606,600USD92
2019-01-01 to 2019-09-30-6,172,399USD273
2019-04-01 to 2019-06-30-2,046,454USD91
2019-01-01 to 2019-03-31-2,519,345USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2020-01-01 to 2020-09-30-6,212,413USD274
2019-01-01 to 2019-09-30-5,036,469USD273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2020-01-01 to 2020-09-30259,480USD274
2019-01-01 to 2019-09-300USD273

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2020-07-01 to 2020-09-3016,863USD92
2020-01-01 to 2020-09-30252,420USD274
2019-07-01 to 2019-09-30142,071USD92
2019-01-01 to 2019-09-30782,928USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2020-01-01 to 2020-09-3031,886,098USD274
2019-01-01 to 2019-09-304,566,988USD273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2020-01-01 to 2020-09-305,727,327USD274
2019-01-01 to 2019-09-302,984,757USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2020-09-30-83,859,827USD
At 2019-12-31-74,380,731USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2020-09-30603,719USD
At 2019-12-31442,806USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2020-01-01 to 2020-09-301,478,934USD274
2019-01-01 to 2019-09-30572,651USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-3,914,077USD92
2020-01-01 to 2020-09-30-9,509,431USD274
2019-07-01 to 2019-09-30-1,627,661USD92
2019-01-01 to 2019-09-30-6,250,519USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2020-09-3035,491,389USD
At 2019-12-3110,544,728USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2020-09-302,277,960USD
At 2019-12-31897,992USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2020-09-303,248USD
At 2019-12-316,495USD

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

PeriodValueUnitDays
2019-01-01 to 2019-09-30193USD273

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2020-07-01 to 2020-09-303,930,940USD92
2020-01-01 to 2020-09-309,761,851USD274
2019-07-01 to 2019-09-301,769,732USD92
2019-01-01 to 2019-09-307,033,447USD273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2020-07-01 to 2020-09-302,629,267USD92
2020-01-01 to 2020-09-305,711,896USD274
2019-07-01 to 2019-09-30857,764USD92
2019-01-01 to 2019-09-304,313,056USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2020-09-3020,211,602shares
At 2019-12-315,227,398shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2020-09-3035,300,340USD
At 2019-12-313,899,328USD
At 2019-09-307,060,373USD
At 2018-12-314,545,097USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2020-09-300USD
At 2019-12-31-757USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2020-09-301,281,306USD
At 2019-12-311,021,826USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2020-09-30677,587USD
At 2019-12-31579,020USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2020-09-30174,186USD
At 2019-12-31571,382USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-3,910,124USD92
2020-01-01 to 2020-09-30-9,478,339USD274
2019-07-01 to 2019-09-30-1,606,600USD92
2019-01-01 to 2019-09-30-6,184,792USD273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2020-07-01 to 2020-09-301,301,673USD92
2020-01-01 to 2020-09-304,049,955USD274
2019-07-01 to 2019-09-30911,968USD92
2019-01-01 to 2019-09-302,720,391USD273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2020-01-01 to 2020-09-3098,567USD274
2019-01-01 to 2019-09-3096,787USD273

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2020-01-01 to 2020-09-30101,814USD274
2019-01-01 to 2019-09-30129,245USD273

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2020-01-01 to 2020-09-303,247USD274
2019-01-01 to 2019-09-3032,457USD273

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2020-07-01 to 2020-09-303,953USD92
2020-01-01 to 2020-09-3030,335USD274
2019-07-01 to 2019-09-3021,061USD92
2019-01-01 to 2019-09-3078,120USD273

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2020-01-01 to 2020-09-300USD274
2019-01-01 to 2019-09-300USD273

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2020-01-01 to 2020-09-300USD274
2019-01-01 to 2019-09-300USD273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2020-01-01 to 2020-09-3025,908,269USD274
2019-01-01 to 2019-09-304,564,409USD273

Inspect the source

Entity
CAPRICOR THERAPEUTICS, INC. / CIK 0001133869
Captured
2026-09-20T07:41:24.575Z
SEC response SHA-256
b9f947143784aa2a5b7cc0470638338f21bd5664475f1be49c554014f98dbf5c

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001133869.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))